Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study.
The proportion of people surviving pancreatic cancer is extremely low, with just 10% of patients diagnosed with any stage of the disease living beyond 1 year and a 5-year relative survival rate of <5%. The lack of effective therapy is one the main reason for such a bleak outlook. Herein, we report on a patient with pancreatic adenocarcinoma and metastatic disease treated with a combination regimen of gemcitabine and lenalidomide, without major complications. We also present in vitro data that highlight a hyper-additive effect of the two drugs when used in combination. To date, 33 months after diagnosis, the patient remains well and continues in full-time employment.
Department of Oncology, Division of Cellular and Molecular Medicine, St George's University of London, 2nd Floor, Jenner Wing, London SW17 0RE, UK. w.liu@sgul.ac.uk
Wai M
WM
Liu
Shiyam
S
Nizar
Angus G
AG
Dalgleish
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D000093542:Gemcitabine
D003841:Deoxycytidine; D013792:Thalidomide; D000077269:Lenalidomide; D000093542:Gemcitabine